Table 2.
Driver‐gene mutation status in successfully established BDXs and their corresponding parental tumors
| Patient information | BDX information | ||||||
|---|---|---|---|---|---|---|---|
| ID | Age (years) | Gender† | Smoking status‡ | Stage | Pathology | Genotype status | Genotype status |
| 27 | 59 | 1 | 1 | IIIA | SCC | FGFR1 AMP | FGFR1 AMP |
| 37 | 55 | 2 | 0 | IV | ADC | EML4‐ALK | EML4‐ALK |
| 54 | 63 | 1 | 1 | IV | SCC | KRAS G34T | KRAS G34T |
| 68 | 76 | 1 | 1 | IIIB | SCC | FGFR1 AMP | FGFR1 AMP |
| 74 | 53 | 1 | 1 | IV | SCC | FGFR1 AMP | FGFR1 AMP |
| 84 | 67 | 1 | 1 | IV | SCC | FGFR1AMP | FGFR1 AMP |
| 133 | 62 | 1 | 1 | IIIA | SCC | FGFR1AMP | FGFR1 AMP |
| 184 | 64 | 1 | 1 | IIB | SCC | EGFR L858R | EGFR WT |
†1: male, 2: female. ‡0: non‐/mild smokers, 1: former/current smokers. ADC, adenocarcinoma; AMP, amplification; BDX, biopsy‐derived xenograft; EGFR, epidermal growth factor receptor; EML4‐ALK, echinoderm microtubule associated protein like 4‐anaplastic lymphoma kinase; FGFR1, fibroblast growth factor receptor‐1; KRAS, v‐Ki‐ras2 Kirsten rat sarcoma viral oncogene; SCC, squamous cell carcinoma; WT, wild‐type.